Be the first to receive investor updates.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce tortor nulla, efficitur at magna sed, gravida venenatis lectus. Sed viverra est ac lectus viverra, condimentum efficitur metus condimentum.

Success! Your contact information has been successfully added to Clearmind Medicine's list.

Oops! Something went wrong while subscribing. Please try again.

Clearmind is proud to host Dr. Gabor Maté to discuss Alcohol Use Disorder and Trauma. View Event

Revolutionary Psychedelics for Treating Addiction & Mental Health

Clearmind Medicine develops breakthrough treatments for binge behaviour and mental health, including alcohol use disorder, binge eating and depression.

Upcoming Event

Psychedelics for Alcoholism

Alcohol Use Disorder, Addiction & Trauma with Dr. Gabor Maté

February 3, 2022

,

9am PST | 12pm EST

Clearmind is proud to host Dr. Gabor Maté to discuss Alcohol Use Disorder and Trauma, and how Clearmind’s candidate treatment may create a clear path to dealing with trauma.

Learn More
View All

Our First Indication

Alcohol Use Disorder

Over 57 million Americans report four or more episodes of heavy drinking per month...

... With an average of seven drinks per episode.1

Over 18 million Americans struggle with Alcohol Use Disorder2—the inability to reduce alcohol consumption
55% of victims of intimate partner violence report alcohol abuse by their abusive partner.3
Approximately half of all sexual assaults are committed by men who had been drinking alcohol.4
35% of parental child abuse offenders consumed either alcohol or drugs at the time of the incident.5

Featured Event

Alcohol Use Disorder, Addiction & Trauma with Dr. Gabor Maté

February 3, 2022
9am PST | 12pm EST

Clearmind is proud to host Dr. Gabor Maté to discuss Alcohol Use Disorder and Trauma, and how Clearmind’s candidate treatment may create a clear path to dealing with trauma.

Learn More

The Economic Cost

Alcohol and substance abuse have a higher economic burden than heart disease, depression and other leading health problems.

The Competition

Large Market & Competitive Density

Our Solution

MEAI: A New Psychoactive Molecule

5-Methoxy-2-aminoindane, or "MEAI"

MEAI exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages with potential to change the lives of millions who struggle to drink in moderation.

How MEAI Works

Mark Haden, Clearmind’s VP Business Development, describes the MEAI treatment experience.

“It’s the ‘enough’ switch. [MEAI] signals to the brain that it is satisfied, that it wants nothing.”

—Ezekiel Golan, Special Advisor for Innovation and New Initiatives

Why MEAI is Different

A New and Unique Psychedelic Treatment

Our Patents

A Portfolio of 20 Patent Filings

Clearmind patents consist of 4 utility patent families owned by the company.
These include 7 granted patents and 13 pending applications.

Our Treatments

Proprietary Treatment Candidates

Our CEO

An experienced public company leader and a skilled navigator of clinical trial processes, Dr. Zuloff-Shani is leading the Clearmind team.

Adi Zuloff-Shani, PhD

Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.

News Releases

View All

Join Us

Let's make history.

Reason for Inquiry

Information

Success! Thank you for contacting Clearmind. We will get back to you as soon as possible.

Oops! Something went wrong. Please try again.